Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Defibrotide sodium by Jazz Pharmaceuticals for Sickle Cell Disease: Likelihood of Approval
Defibrotide sodium is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Sickle Cell Disease. According to...
Data Insights
Defibrotide sodium by Jazz Pharmaceuticals for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease): Likelihood of Approval
Defibrotide sodium is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Mucocutaneous Lymph Node Syndrome (Kawasaki...